

Expression of Concern

Expression of Concern on “A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements”

BioMed Research International

Received 25 April 2022; Accepted 25 April 2022; Published 13 September 2022

Copyright © 2022 BioMed Research International. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements” [1], Reference [31] referred to a study using Vivomixx®. We have recently been made aware of a concern regarding the described composition of the Vivomixx® product, and the publishers of the study protocol [2] and results [3] have been informed. These articles may be subject to correction.

References

- [1] B. S. Sivamaruthi, P. Kesika, N. Suganthi, and C. Chaiyasut, “A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements,” *BioMed Research International*, vol. 2019, Article ID 3291367, 20 pages, 2019.
- [2] S. I. Halkjaer, L. Nilas, E. M. Carlsen et al., “Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: study protocol for a randomized controlled trial,” *Trials*, vol. 17, no. 1, p. 491, 2016.
- [3] S. I. Halkjær, V. E. de Knecht, B. Lo et al., “Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women: Results from a Randomized, Double-Blind Placebo-Controlled Study,” *Current Developments in Nutrition*, vol. 4, no. 7, article nzaa095, 2020.